Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.57 |
| ▸ | PDE4A | P27815 | 15/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558312 | 0.98 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL2827366 | 0.95 | PDE4B (0.59) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL77276 | 0.92 | PDE4B (0.59) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL29798131 | 0.86 | PDE4A (0.78) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7211275 | 0.86 | PDE4A (0.78) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL21874325 | 0.86 | KMT2A (0.50) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL29859032 | 0.86 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL21820761 | 0.86 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9APDE4B | |
| SCHEMBL30683833 | 0.84 | PDE4A (0.80) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL23325964 | 0.84 | PDE4B (0.53) | MEN1KMT2ANPC1RAB9APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-02-09 | — | — | US | disclosed |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-7598412-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-20050148648-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| US-5405866-A | Administering with cytostatic drugs to treat drug resistant tumors | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5302727-A | For use with antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5223530-A | Selective high-affinity ligands for treatment of psychological disorders, side effect reduction | SRI, INTERNATIONAL (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0523493-A1 | Dithianes | F. HOFFMANN-LA ROCHE AG (CH) | 1993-01-20 | — | — | EP | disclosed |
| EP-0495084-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002481-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5086054-A | Selective high-affinity ligands to sigma boding sites, administering, amipsychotic, antiarrhythmia, antiischemic agents anticonvulsants, reduced side effects | SRI INTERNATIONAL (US) | 1992-02-04 | — | — | US | disclosed |
| US-4843081-A | Aryl and heteroaryl substituted cycloalkyl compounds | RORER PHARMACEUTICAL CORPORATION (US) | 1989-06-27 | — | — | US | disclosed |
| US-4795757-A | Bisarylamines | RORER PHARMACEUTICAL CORPORATION (US) | 1989-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148648-A1 | Modulators of ATP-binding cassette transporters | ABCB11, ABCB1, ABCC5 | MEN1 4405/4885KMT2A 4175/4885NPC1 36/4885 |
| US-20130012536-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | ABCB11, ABCB1, ABCC5 | MEN1 4405/4885KMT2A 4175/4885NPC1 36/4885 |
| US-20100125090-A1 | Modulators of ATP-Binding Cassette Transporters | ABCB11, ABCB1, ABCC5 | MEN1 4405/4885KMT2A 4175/4885NPC1 36/4885 |
| US-20120035179-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | ABCB11, ABCB1, ABCC5 | MEN1 4405/4885KMT2A 4175/4885NPC1 36/4885 |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | EHMT1, EHMT2, EZH2 | MEN1 595/4885KMT2A 6/4885NPC1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.